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 2 
Main points; Activation of Gq-coupled receptors S1P2 and S1P3 by S1P triggers Ca2+ influx 
through TRPC6, which results in MAPK activation and increased secretion of the 
proinflammatory or neuroprotective chemokine CXCL1 in astrocyte in vitro. 
 







  A biologically active lipid, sphingosine-1-phosphate (S1P) is highly abundant in blood, and 
plays an important role in regulating the growth, survival, and migration of many cells. Binding 
of the endogenous ligand S1P results in activation of various signaling pathways via G 
protein-coupled receptors, some of which generates Ca2+ mobilization. In astrocytes, S1P is 
reported to evoke Ca2+ signaling, proliferation, and migration; however, the precise mechanisms 
underlying such responses in astrocytes remain to be elucidated. Transient receptor potential 
canonical (TRPC) channels are Ca2+-permeable cation channels expressed in astrocytes and 
involved in Ca2+ influx after receptor stimulation. In this study, we investigated the involvement 
of TRPC channels in S1P-induced cellular responses. In Ca2+ imaging experiments, S1P at 1 
µM elicited a transient increase in intracellular Ca2+ in astrocytes, followed by sustained 
elevation. The sustained Ca2+ response was markedly suppressed by S1P2 receptor antagonist 
JTE013, S1P3 receptor antagonist CAY10444, or non-selective TRPC channel inhibitor Pyr2. 
Additionally, S1P increased chemokine CXCL1 mRNA expression and release, which were 
suppressed by TRPC inhibitor, inhibition of Ca2+ mobilization, MAPK pathway inhibitors, or 
knockdown of the TRPC channel isoform TRPC6. Taken together, these results demonstrate that 
S1P induces Ca2+ signaling in astrocytes via Gq-coupled receptors S1P2 and S1P3, followed by 
Ca2+ influx through TRPC6 that could activate MAPK signaling, which leads to increased 




  Astrocytes are the most abundant cells in the CNS and play diverse roles in the regulation of 
neuronal activity, vascular function, and gliotransmitter release [Mulligan and MacVicar, 2004; 
Khakh and Sofroniew, 2015; Verkhratsky et al., 2016]. By contrast, pathologically activated 
astrocytes have been reported to show astrogliosis, which can cause neuronal dysfunction in 
neurodegenerative diseases [Allaman et al., 2011; Sofroniew, 2009]. Although, astrocytes are 
electrically nonexcitable, they can be excited by Ca2+ signaling [Bazargani and Attwell, 2016; 
Fiacco and McCarthy, 2006; Rusakov, 2015].  
  Transient receptor potential canonical (TRPC) channels, Ca2+-permeable nonselective cation 
channels, function as homo- or heterotetrameric channels and at least one of seven isoforms is 
expressed in almost every tissue where they facilitate voltage-independent Ca2+ entry in 
response to store depletion induced by receptor stimulation [Birnbaumer, 2009]. In astrocytes, 
several isoforms of TRPC channels play important roles in astrocytic Ca2+ responses induced by 
store depletion [Golovina, 2005], diacylglycerol activation [Grimaldi, 2006], mechanical 
stimulation or ATP [Beskina et al., 2007], and thrombin [Shirakawa et al., 2010]. 
  Sphingosine-1-phosphate (S1P) is a biologically active sphingolipid that plays an important 
role in regulating the growth, survival and migration of mammalian cells [Brinkmann, 2007; 
Pyne and Pyne, 2010]. In astrocytes, S1P induces cellular proliferation [Malchinkhuu et al., 
2003], morphological changes [Rouach et al., 2006], and cellular migration [Fischer et al., 2011]. 
Moreover, S1P induces expression of a variety of neurotrophic factors, such as GDNF 
[Yamagata et al., 2003], NGF [Furukawa et al., 2007] and cytokines, such as interleukin (IL) 1β 
and CCL2 [Zhou and Murthy, 2004] in astrocytes. Moreover, S1P activates the Gq/11 inositol 
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lipid/ Ca2+ signaling pathway in cortical astrocytes [Sorensen et al., 2003]. However, the precise 
molecular mechanisms underlying S1P-induced Ca2+ responses and functional changes in 
astrocytes remain unknown. Thus, we focused on and investigated the involvement of TRPC 
channels in S1P-induced functions in primary cultured astrocytes. To examine the role of TRPC 
channels in S1P-induced astrocytic responses, we examined Ca2+ responses, morphological 
changes, migration, and cytokine release. Here, we provide the first indication of the possibility 
that TRPC6 channels are involved in S1P-induced Ca2+ responses and CXCL1 release. 
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Materials and Methods 
 
Cultured rat cortical astrocyte 
All experiments were conducted in accordance with the ethical guidelines of the Kyoto 
University Animal Research Committee. Primary astrocyte-enriched cultures were prepared 
from cerebral cortices of 0–2 d-old postnatal Wistar/ST rats (Japan SLC, Hamamatsu, Japan), as 
previously described [Shirakawa et al., 2010] with slight modification. Cells were dissociated 
with 3 mg/ml dispase (Gibco, Tokyo, Japan), and were plated in 75 cm2 bent-cap flasks with 7 
ml of Eagle’s Minimum Essential Medium (EMEM; Nissui Pharmaceutical, Tokyo, Japan) 
containing 10% heat-inactivated fetal bovine serum (FBS; JRH Biosciences, Lenexa, USA) in 
an incubator with 5% CO2 at 37°C. After cultivation for 2–4 weeks, the flasks were shaken on 
an orbital shaker at 250 rpm for 14–17 h at 37°C to remove microglia and oligodendrocytes. 
The remaining astrocytes were detached with 0.25% trypsin (Gibco), resuspended in fresh 
medium, and reseeded on 10 mm glass coverslips, 35 mm dishes or 48 well plates at a density 
of 2.5×104 cells/cm2. Cells were used at least 4-5 days before being used for experiments. 
Unless otherwise noted, all experiments were performed under serum starvation. 
 
Reverse transcription (RT)-PCR  
Total RNA was extracted from astrocytes in a 35 mm dish using a Nucleo Spin® RNA kit 
(TaKaRa Bio, Shiga, Japan). Using 1 µg of total RNA, two-step reverse transcription (RT)-PCR 
was performed with the ReverTra Ace® RT-PCR Kit (Toyobo, Osaka, Japan) using a PCR 
Thermal Cycler Dice® Gradient (Takara Bio; TP600). The pairs of primers used for 
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amplification were 5'-GAAGTTCCACCGGCCCATGT-3' and 
5'-GGAGATGTTCTTGCGGAAGG-3' for S1P receptor 1 (S1P1), 
5'-GTCTGGACCATCTGGAGGCT-3' and 5'-GTCTGAGGACCAGCAACGTC-3' for S1P 
receptor 2 (S1P2), 5'-GACGCCAACAAGAAGCACCG-3' and 
5'-GCTGATGAGAAAGGCAATGTA-3' for S1P receptor 3 (S1P3), 
5'-TGGGGTGCCCAGAGGAGTCG-3' and 5'-CTAGCCAGCCTGCCGCTGTG-3' for S1P 
receptor 4 (S1P4), 5'-GCCTATGTGCTCTTCTGCGT-3' and 
5'-CAACGACCGTGGCGTGTG-3' for S1P receptor 5 (S1P5), 
5’-AAGAACTGCAGTCCTTCGTTG-3’ and 5’-TCTGCATCTTCTGTCGCATG-3’ for TRPC1, 
5’-TCTGTTGTCCTCAAATATGACCAC-3’ and 5’-TCTCGAGTTAGACTGAGTGAAGAG-3’ 
for TRPC3, 5’-CTGGTCAAGTGGATATGGACG-3’ and 5’-CTTCGCTGTGGCTCTTCTC-3’ 
for TRPC4, 5’-TGGTTCAACAACACCTTCTGTC-3’ and 
5’-ACCATTAAACTTGGAGAACAGGAG-3’ for TRPC5, 
5‘-CGGATGTGGAGTGGAAGTTTG-3’ and 5’-CATAACGGAGACTTGAGATGTCC-3’ for 
TRPC6, and 5’-TGAAGTACGACCACAAGTTCATC-3’ and 
5’-GCACGTATCTCTTAATGAGACGC-3’ for TRPC7. The temperature cycles were 94°C for 2 
min, followed by 35 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 45 s. Amplified PCR 
products were electrophoresed in a 1.2% TAE agarose gel and visualized under UV light with 
0.1 µg/ml ethidium bromide by using a ChemiDoc XRS (Bio-Rad, Hercules, CA, USA). Images 
were captured with Quantity One software (Bio-Rad). 
 
Measurement of intracellular Ca2+ concentrations 
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Intracellular Ca2+ concentration ([Ca2+]i) was monitored using the fluorescent calcium indicator 
fura 2-AM (Dojindo, Kumamoto, Japan), as previously described [Miyake et al., 2015]. 
Astrocytes were cultured on 10 mm glass coverslips and grown for 4–5 d. For dye loading, the 
cells on a coverslip were loaded for 30 min with 5 µM fura 2-AM in Krebs-Ringer solution (140 
mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM glucose, 10 mM HEPES) containing 
0.01% cremophor EL (Sigma-Aldrich). Cells were washed with Krebs-Ringer solution and set 
on an imaging chamber. For the Ca2+ -free experiments, CaCl2 was omitted, and 0.5 mM EGTA 
was added to the external solution. Loaded cells were transferred into a perfusion chamber with 
fresh buffer and mounted on a Nikon fluorescent microscope equipped with an 
AQUACOSMOS/ORCA-AG imaging system (Hamamatsu Photonics, Shizuoka, Japan). 
Fluorescent images were scanned at 500 nm and 2 sec intervals, with alternate excitation at 340 
and 380 nm at room temperature. The fluorescence ratio of individual cells is designated 
F340/380. Each experiment was repeated more than three times. 
 
Quantitative RT-PCR 
After RT of total mRNA to cDNA using ReverTra Ace® qPCR RT Master Mix (Toyobo), 
real-time quantitative PCR was performed using the StepOne real-time PCR system (Applied 
Biosystems, Darmstadt, Germany) in a final volume of 20 µl containing 0.5 µg of total RNA 
with THUNDERBIRD SYBR qPCR Mix (Toyobo). The oligonucleotide primers used for 18S 
ribosomal RNA (rRNA) were 5’-CGGTCCAAGAATTTCACCTC-3’ and 
5’-ACCGCGGTTCTATTTTGTTG-3’, for BDNF were 
5’-GAAGGCTGCAGGGGCATAGAC-3’ and 5’-TACACAGGAAGTGTCTATCCTTAT-3’, for 
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GDNF were 5’-CTCGAAGAGAGAGGAACCGGCAAG-3’ and 
5’-CTGGAGCCAGGGTCAGATACATCC-3’, for NGF were 
5’-CAGAGTTTTGGCCTGTGGT-3’ and 5’-GGACATTACGCTATGCACCTC-3’, for COX-2 
were 5’-GATCACATTTGATTGACAGC-3’ and 5’-TCCTTATTTCCTTTCACACC-3’, for 
ICAM1 were 5’-TATCGGGATGGTGAAGTCTG-3’ and 
5’-ATTCTGATCATGGTACAGCAC-3’, for IL6 were 5’-ACTTCACAGAGGATACCAC-3’ 
and 5’-GCATCATCGCTGTTCATAC-3’, for CCL5 were 
5’-CCAGAGAAGAAGTGGGTTCA-3’ and 5’-AGCAAGCAATGACAGGAAAG-3’, for 
CXCL10 were 5’-TGAAAGCGGTGAGCCAAAGA-3’ and 
5’-TAGCCGCACACTGGGTAAAG-3’, for CXCL1 were 5’-CAGCGCTGCACAGAGAAG-3’ 
and 5’-GACTCCAGCCACACTCCAA-3’ and TRPC6 were 
5-‘AGGAAATTGAGGATGATGCGG-3’ AND 5’-CCCTGGATAAGCTCAGACATCC-3’. The 
temperature cycles were 95°C for 10 min, followed by 35 cycles of 95°C for 15 s and 60°C for 
60 s. The results were analyzed with Primer Express software (Applied Biosystems). The 
identity of the PCR product was confirmed by automated determination of the melting 
temperature of the PCR products. The results for each gene were normalized to 18S rRNA 
levels measured in parallel in each sample. 
 
Measurement of CXCL1 
CXCL1 release or content was measured using a rat CXCL1/CINC-1 Quantikine ELISA Kit 
(R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. For the assay, 
cells were grown in 48 well plates for at least 1 week. After serum starved overnight, cells were 
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treated with S1P or vehicle control for 48 h in the absence or presence of each inhibitor. After 
the treatments, 50 µL of culture supernatant was analyzed. 
 
Western blotting 
Western blotting was performed as described previously [Shirakawa et al., 2010], with slight 
modification. The drugs-treated cells were collected by a brief centrifugation and were lysed in 
RIPA buffer (Nacalai tesque, Kyoto, Japan) supplemented with phosphatase inhibitor cocktail 2 
and 3 (P5726 and P0044, Sigma Aldrich). Proteins were diluted in NuPAGE® 4x LDS sample 
buffer (Life Technologies, Carlsbad CA, USA), loaded onto a 10% SDS-polyacrylamide gel, 
and blotted onto Immobilon-P PVDF transfer membranes (Millipore, Bedford, MA, USA). 
After a blocking step using Blocking One-P (Nacalai tesque), the membranes were incubated 
overnight at 4°C with primary antibodies, which were all purchased from Cell Signaling 
Technologies, (Beverly, MA, USA) diluted 1:1000 in Tris-buffered saline containing 0.1% 
Tween-20 and 10% Blocking One-P. Phosphorylated proteins were detected using rabbit 
monoclonal or polyclonal antibodies against phospho-p44/42 MAPK (Erk1/2) (#9101), 
phospho-SAPK/JNK (#4671) and phospho-p38 MAPK (#9211) followed by incubation with 
peroxidase-conjugated donkey anti-rabbit IgG (1:5000 dilution; GE Healthcare, Little Chalfont, 
UK) for 1 h at RT. Specific bands were detected by Immobilon Western Chemiluminescent HRP 
substrate (Millipore) and visualized using the ChemiImager 4400 imaging system (Alpha 
Innotech, San Leandro, CA, USA). To normalize for total protein loading, blots were stripped 
and reprobed with rabbit polyclonal antibodies against SAPK/JNK (#9252), p44/42 MAPK 
(Erk1/2) (#9102), or p38 MAPK (#9212) followed by the same procedure as described above. 
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The bands were densitometrically quantified using ImageJ software. 
 
TRPC6 siRNA transfection 
TRPC6-specific siRNA was used to block TRPC6-mediated signaling. Astrocytes were 
transfected with Stealth™ RNAi Negative Control Medium GC Duplex or Stealth™ select 
RNAi for rat TRPC6 (Life Technologies) using Lipofectamine 2000 transfection reagent (Life 
Technologies) according to the manufacturer’s instructions. The Stealth™ select RNAi 
sequence for rat TRPC6 was 5’-UUCAAUAGGAGAUAAAGCAGGGACU-3’ and 
5’-AGUCCCUGCUUUAUCUCCUAUUGAA. After 6 h of treatment with siRNA, the medium 
was replaced and the cells were incubated for 48 h. The transfection rate was calculated to be 
≥90%, as estimated by the percentage of cells that were fluorescein isothiocyanate-positive after 




S1P-induced morphological changes were detected by actin staining, as previously described 
[Shirakawa et al., 2010; Miyanohara et al., 2015]. After pre-treatment with serum-free EMEM 
for 10 min, cells on 10 mm glass coverslips (Matsunami Glass, Osaka, Japan) were treated with 
the drug of interest for 3 h. Following fixation with 4% para-formaldehyde, the cells were 
soaked in 0.2% Tri-ton-X100 for permeabilization, and then incubated for 1 h at 4°C with rabbit 
Alexa Fluor488-conjugated phalloidin (1:40 dilution; Invitrogen, Carlsbad, CA, USA) to 
visualize the actin cytoskeleton. Before observation with a fluorescence microscope, 0.01 
 12 
mg/ml Hoechst 33342 was added to the cells on the glass for nuclear staining. Astrocyte were 
defined as “polygonal cells” in the morphology if they exhibit polygonal shapes with an 
increase in their F-actin content adjacent to the cell membrane and do not display multipolar 
shapes with diffuse F-actin extending short protrusions, which were commonly observed in 
control treatment under serum starvation. Morphological changes were calculated as the 
percentage of polygonal-shaped astrocytes to the total number of Hoechst-positive cells. 
 
Scratch-wound assay  
After enrichment of the cortical astrocytes, the cells were reseeded on 35 mm dishes and 
cultured for 1–2 weeks. Following serum starvation for 24 h, the medium was removed, and a 
reference line was drawn. A scratch was made in the astrocyte monolayer with a 1 ml pipette tip 
along the reference line, creating 4–8 scratched areas. Cells were washed twice with 
phosphate-buffered saline to remove cell debris, and fresh serum-free media containing the 
drugs of interest were added. Images were taken at 0 and 72 h, with the same field recorded in 
each case. To determine the area of migration, the leading edge of the scratched cells at 0 h was 
superimposed onto the image taken at 72 h. After treatments, measurements from 4–8 areas 
were averaged to determine the area of migration. 
 
Statistical analysis 
Data were expressed as means ± S.E.M. The statistical significance of the differences among 
groups was determined by a one-way analysis of variance (ANOVA) followed by Tukey’s 
multiple comparison tests using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) 
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and a p-value of less than 5% was considered significant. 
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Results 
S1P receptors S1P1, S1P2, and S1P3 are expressed in primary rat cortical astrocytes 
S1P receptors are a family of G protein-coupled receptors (GPCRs), consisting of five members 
called S1P1, S1P2, S1P3, S1P4, and S1P5 [Brinkmann, 2007; Pyne and Pyne, 2010]. First, we 
investigated the expression of the S1P receptor subtypes in cultured rat primary cortical 
astrocytes. RT-PCR analysis of mRNA extracted from cultured astrocytes detected the 
expression of S1P1, S1P2, and S1P3 but not S1P4 and S1P5 (Fig. 1A). 
 
S1P induces Ca2+ mobilization in cultured cortical astrocytes via Gq-coupled receptors S1P2 
and S1P3 
S1P stimulates the Gq/11-inositol lipid/Ca2+ signaling pathway in cortical astrocytes [Sorensen et 
al., 2003]. To investigate S1P-induced Ca2+ responses, [Ca2+]i was measured by Ca2+ imaging 
experiments using fura-2 AM, with the finding that S1P evoked Ca2+ responses in a 
concentration-dependent manner and that the responses consisted of a large and transient 
increase in [Ca2+]i, followed by a sustained increase (Fig. 1B-E). We assessed the Ca2+ responses 
by quantifying the transient increase in [Ca2+]i resulting from Ca2+ release from the endoplasmic 
reticulum (ER), called the “peak amplitude”, and the persistent increase in [Ca2+]i resulting from 
Ca2+ entry as the “sustained level”. 
  To investigate which S1P receptor subtypes are responsible for S1P-induced Ca2+ 
mobilization, we examined whether S1P1 stimulation can evoke Ca2+ responses and found that a 
selective S1P1 agonist SEW2871 (10 µM) did not evoke Ca2+ responses (Fig. 1F). Next, we 
examined whether Ca2+ responses are suppressed by either an inhibitor of Gq-coupled receptor 
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S1P2 or S1P3. A selective S1P2 inhibitor JTE013 (1 µM) significantly but partially suppressed 
both the peak amplitude and the sustained increase of [Ca2+]i (Fig. 1G), and a selective S1P3 
inhibitor CAY10444 (10 µM) had a tendency to suppress peak amplitude and significantly but 
partially suppressed the sustained Ca2+ response (Fig. 1H). In addition, PLC inhibitor U73122 (1 
µM) completely inhibited the S1P-induced Ca2+ elevation (Fig. 1I), while the Gβγ subunit 
activity inhibitor gallein (10 µM) had no effect on the Ca2+ responses (Fig. 1J), suggesting that 
Gq protein, but not Gβγ, is involved in these observed Ca2+ responses. Taken together, these 
results suggest that S1P induces Ca2+ responses via the Gq-coupled receptors S1P2 and S1P3. 
 
S1P-induced Ca2+ responses can be attributed to TRPC-mediated extracellular Ca2+ entry in 
cultured astrocytes 
We investigated the contribution of extracellular Ca2+ to the S1P-induced response in astrocytes. 
Under Ca2+-free conditions, only transient Ca2+ elevation, without subsequent sustained 
increases in [Ca2+]i, was observed (Fig. 2A), suggesting that the sustained increase in [Ca2+]i 
was dependent on the extracellular Ca2+ level. In addition, we examined the involvement of the 
TRP channels, which are Ca2+-permeable cation channels, using non-selective TRP channel 
inhibitors Gd3+ (10 µM) and La3+ (10 µM). Gd3+ and La3+ significantly suppressed the sustained 
Ca2+ responses, but not the peak amplitude (Fig. 2B, C).  
  TRPC channels are activated by diacylglycerol activation [Birnbaumer, 2009], which occurs 
after Gq-coupled receptor stimulation and contributes to Ca2+ responses in astrocytes [Grimardi, 
2006]. We investigated the expression of TRPC channels by RT-PCR analysis and detected 
specific high-intensity bands for TRPC1, C4, and C6 and a relatively low-intensity band for 
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TRPC3 and C5 (Fig. 2D). We investigated the involvement of TRPC channels in S1P-induced 
Ca2+ responses. Application of the non-selective TRPC inhibitor Pyr2 significantly inhibited the 
peak amplitude and sustained increase in [Ca2+]i (Fig. 2E). On the other hand, the selective 
TRPC3 inhibitor Pyr3 did not affect the S1P-induced sustained increase in [Ca2+]i, while it 
significantly, albeit weakly, suppressed the peak amplitude (Fig. 2F), indicating that TRPC6 is 
involved in both S1P-induced peak amplitude and sustained increase in [Ca2+]i. 
 
S1P-induced morphological change is independent of Ca2+ signaling mediated by TRPC 
channels  
S1P rearranges the actin cytoskeleton, leading to changes in astrocytic morphology [Rouach et 
al., 2006]. Staining with fluorescence-conjugated phalloidin revealed that continuous 
application of S1P (1 µM) for 3 h caused actin cytoskeletal rearrangements and retraction of the 
protrusions in serum-starved astrocytes, most of which exhibited a typical polygonal shape (Fig. 
3). BAPTA-AM (3 µM), Pyr2 (10 µM), and Pyr3 (10 µM) all failed to inhibit this S1P-induced 
actin rearrangement with a polygonal morphology and cells treated with these reagents looked 
similar to those exposed to S1P (Fig. 3), indicating that S1P-induced morphological change is 
independent of TRPC activation in astrocytes. 
 
S1P-induced astrocytic migration is independent of TRPC channel-mediated Ca2+ signaling  
S1P promotes cellular migration in rat cortical astrocytes [Mullershausen, 2007]. Next, using a 
scratch-wound assay on a monolayer of pure astrocytes, we examined the effects of Pyr2 or 
Pyr3 on astrocytic migration and found that S1P significantly increased astrocytic migration and 
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that neither Pyr2 (10 µM) nor Pyr3 (10 µM) affects S1P-induced astrocytic migration (Fig. 4), 
suggesting that S1P-induced migration is independent of TRPC activation in astrocytes. 
 
S1P increases CXCL1 expression and release from astrocytes via Gq-coupled receptors S1P2 
and S1P3 
Physiologically or abnormally activated astrocytes may produce and release some cytokines, 
inflammatory factors, and neurotrophic factors [Allaman et al., 2011; Verkhratsky, 2016]. 
Additionally, S1P-treated astrocytes release GDNF [Yamagata et al., 2003], NGF [Furukawa et 
al., 2007], Il1β, and CCL2 [Zhou et al., 2004]. Therefore, we investigated changes in the 
expression level of various factors 24 h after treatment with 1 µM S1P. Among tested genes, we 
found that the mRNA for only CXCL1, one of the CXC chemokines, was significantly 
upregulated in S1P-treated astrocytes (Fig. 5A-H). Using ELISA assay, we measured the content 
of CXCL1 in the culture medium of astrocytes treated with S1P (1 µM) after 24 h and found 
that S1P increased the CXCL1 release, which was significantly inhibited by the S1P2 receptor 
inhibitor JTE013 at 1 µM and the S1P3 receptor inhibitor CAY10444 at 10 µM, but not the S1P1 
receptor inhibitor VPC44116 at 1 µM (Fig. 5I). These findings indicate that S1P increased 
CXCL1 production and release via Gq-coupled receptors S1P2 and S1P3 in astrocytes (Fig. 5I). 
 
S1P-induced CXCL1 release is mediated by TRPC6, Ca2+ signaling, and the MAPK pathway 
Finally, we investigated the mechanisms underlying S1P-induced CXCL1 release. 
Mitogen-activated protein kinases (MAPKs), a family of serine/threonine kinases, link receptor 
activation in the cell membrane to gene expression in the nucleus [Chang and Karin, 2001]. We 
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examined the phosphorylation levels of MAPKs, such as ERK, JNK and p38, in the presence 
and absence of S1P and found that phosphorylation levels of all MAPKs significantly increased 
in S1P-stimulated astrocytes (Fig. 6A). Moreover, S1P-induced CXCL1 release was 
significantly inhibited by MEK inhibitor PD98059 (30 µM), JNK inhibitor SP600125 (SP) (30 
µM), or p38 inhibitor SB203580 (SB) (30 µM) (Fig. 6B). The non-selective TRPC channel 
inhibitor Pyr2 (1–10 µM), but not the selective TRPC3 inhibitor Pyr3, significantly inhibited the 
increase in CXCL1 release (Fig. 6C, D). To determine whether the Ca2+ signal may participate 
in CXCL1 release, we used the PKC inhibitor bisindolylmaleimide I (BIM; 1 µM), ER 
Ca2+-ATPase inhibitor cyclopiazonic acid (CPA; 30 µM), and intracellular Ca2+ chelator 
BAPTA-AM (3 µM) and found that all the drugs significantly blocked S1P-induced CXCL1 
release (Fig. 6E). Collectively, these results suggest that S1P induces Ca2+ entry through TRPC 
channels, which could activate MAPK signaling and result in an increase in CXCL1 release.  
  Among the TRPC channels, TRPC1, 4, and 6 were abundantly expressed in our astrocyte 
preparation, and, since TRPC1 and TRPC4 themselves do not form a functional channel 
[Birnbaumer, 2009; Kiyonaka et al., 2009]. We focused on the role of TRPC6 in mediating 
S1P-induced CXCL1 release. We developed a specific siRNA for TRPC6 (si-TRPC6) and found 
that it reduced the mRNA levels of TRPC6 by more than 50% (Fig. 6F). Subsequently, we 
confirmed selective TRPC6 knockdown using the DAG analogue OAG, which is a direct 
activator of TRPC3, 6, and 7. The percentage of cultured astrocytes responding to OAG was 
also significantly reduced by si-TRPC6 treatment (Fig. 6G-I), indicating that TRPC6 function 
was partially and significantly suppressed with si-TRPC6 treatment. On the other hand, 
treatment with OAG at ranging from 1 to100 μM did not induce CXCL1 release (Fig. 6J), 
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suggesting that OAG alone can induce astrocytic Ca2+ responses, but does not mimic 
S1P-induced CXCL1 release. Moreover, we examined the response to S1P in TRPC6 
down-regulated astrocytes and found that S1P-induced sustained increase, but not the peak 
amplitude, in [Ca2+]i was significantly inhibited by down-regulation of TRPC6 with si-TRPC6 
(Fig. 3K-N). Subsequently, we examined the effects of RNAi-mediated knockdown of TRPC6 
on CXCL1 release. After 24 h of treatment with S1P, si-TRPC6 significantly inhibited 
S1P-induced CXCL1 release (Fig. 6O), demonstrating that TRPC6 contributes to S1P-induced 
Ca2+ responses and CXCL1 release. 
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Discussion 
In this study, we investigated S1P-induced Ca2+ responses and CXCL1 release and found that 
S1P induced stimulation of Gq-coupled receptors S1P2 and S1P3 following Ca2+ influx via 
TRPC6, which resulted in activation of the MAPK pathway and CXCL1 release. 
  Ca2+ signaling via TRPC6 was involved in S1P-induced Ca2+ responses and CXCL1 release 
but not in morphological changes and migration. The reason for this difference is unclear. Since 
S1P induces morphological change via G12/13 and the Rho pathway, proliferation via Gi/o,  
[Sorensen et al., 2003], and migration via S1P1 [Mullershausen et al., 2007], Ca2+ signaling may 
not be important in these cellular responses. On the other hand, we previously reported that a 
thrombin receptor proteinase-activated receptor 1 (PAR1), coupled with Gq/11, G12/13, and Gi/o, 
induces proliferation and morphological changes that are mediated by Ca2+ signaling via TRPC3 
[Shirakawa et al., 2010]. Therefore, whether Ca2+ signaling is involved in cellular function may 
depend on the coupled G protein. S1P evoked a transient Ca2+ peak followed by sustained 
elevation of [Ca2+]i, although thrombin induces a transient Ca2+ response followed by Ca2+ 
oscillation. This different Ca2+ signaling pattern may be attributed to the differences in 
downstream Ca2+-binding proteins or signals. In this study, we demonstrated that TRPC6 is 
involved in S1P-induced responses, but the role of TRPC6 in astrocytes was reported in only 
one study in the literature, which reported increases in TRPC6 expression after IL1β treatment 
that involved OAG-induced Ca2+ responses [Beskina et al., 2007]. Future studies are needed to 
determine the detailed molecular pathways that TRPC6-mediated Ca2+ signaling may regulate in 
astrocytes. 
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  One could question whether S1P-induced TRPC6-mediated Ca2+ signaling can regulate the 
activation of MAPKs pathway. Consistent with the observation in this study, Osinde et al. 
(2007) reported that S1P stimulates ERK phosphorylation via S1P3, but not S1P1 receptors, in 
cultured astrocyte. On the other hand, Sorensen et al. (2003) reported that S1P-induced ERK 
and JNK phosphorylation are dependent on pertussis toxin-sensitive Gi/o proteins, implying that 
Ca2+ signaling is not always necessary to activate MAPK. In this context, Miyabe et al. (2016) 
have reported that S1P at 5 µM induces CXCL1 release in human umbilical vein endothelial 
cells, which is significantly inhibited by a functional S1P1 antagonist ONO-W061. These 
studies suggest the involvement of TRPC6-mediated Ca2+ signaling in S1P-induced MAPKs 
activation and CXCL1 release is partial and there could be other independent parallel pathways. 
  Sphingosine kinase, which can phosphorylate sphingosine to produce S1P, is highly 
expressed in the brain [Fukuda et al., 2003], and the S1P receptors (S1P1-5) that belong to the 
GPCR super family are also expressed in brain cells, including astrocytes [Groves et al., 2013]. 
There have been some reports indicating that S1P induces the expression of some neurotrophic 
factors including GDNF [Yamagata et al., 2003] and NGF [Furukawa et al., 2007] in cultured 
astrocytes, which were not consistent with our observations that rat cultured rat astrocytes did 
not show any change in GDNF and NGF mRNA levels by S1P treatment for 24 h. Since the 
previous studies demonstrate that S1P-induced increase in the mRNA expression levels of NGF 
as well as GDNF can peak at 6-12 h, gradually decline to control level by 24 h, further 
time-course study will be needed to address the discrepancy in the responses to S1P.  
  Conversely, S1P can be involved in neuroinflammatory diseases in various pathological 
conditions. For example, the concentration of S1P in the brain increases after ischemia in a 
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mouse thrombosis model of the middle cerebral artery [Kimura et al., 2008], and S1P 
production is facilitated in reactive astrocytes and activated microglia [Kimura et al., 2007]. 
Also, in the cerebrospinal fluid of multiple sclerosis (MS) patients, the S1P concentration 
[Kułakowska et al., 2010] and S1P1 and S1P3 are upregulated in MS lesions [Van Doorn, 2010]. 
Since S1P concentrations are high in blood but low in tissues [Obinata and Hla, 2012], S1P can 
leak and affect the CNS environment when the blood-brain barrier becomes permeable in some 
pathological conditions. 
  In this study, S1P promoted CXCL1 release after Gq-coupled receptor stimulation. 
Stimulation of other Gq-coupled receptors results in an increase in CXCL1 production or 
secretion. For example, thrombin or agonist of PAR1 induced CXCL1 release from astrocytes 
via Ca2+ signaling [Wang et al., 2007]. Activation of endothelin B receptor also promotes 
CXCL1 production mediated by the NF-κB pathway [Koyama et al., 2013]. Although CXCL1 
can exacerbate inflammation by promoting neutrophil migration in neuroinflammatory diseases, 
CXCL1 production was induced by pro-inflammatory factors, such as LPS [McKimmie and 
Graham, 2010], TNFα [Lee et al., 2012], and IL1β [An et al., 2011], in astrocytes. Treatment 
with a neutralizing antibody for CXCL1 or an antagonist for CXCR1/2, a receptor of CXCL1, 
improves neurological symptoms in murine models of inflammatory pain [Cao et al., 2014], 
cerebral ischemia [Garau et al., 2006], spinal cord injury [Gorio et al., 2007], and cerebral 
hemorrhage [Matsushita et al., 2014]. Since S1P is upregulated in these diseases [Obinata and 
Hla, 2012], so it is conceivable that an increase in CXCL1 production in astrocytes is involved 
in exacerbation of inflammation in these neuroinflammatory diseases. 
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  Meanwhile, CXCL1 also has beneficial effects by promoting oligodendrocyte progenitor 
proliferation [Wu et al., 2000], and controlling positioning of oligodendrocyte precursors [Tsai et 
al., 2002]. In MS mouse models, studies report conflicting results showing that CXCL1 is either 
proinflammatory or neuroprotective [Omari et al., 2006]. Therefore, whether CXCL1 from 
astrocytes promotes neuroinflammation or has a beneficial effect may depend on each 
pathological condition and disease stage.  
  In conclusion, this study demonstrated that S1P induces Ca2+ influxes via TRPC6, which 
activates the MAPK pathway to promote CXCL1 release. Since S1P is upregulated in 
inflammatory diseases, S1P-induced CXCL1 release may be important in inhibiting CNS 
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Fig. 1. Expression of S1P receptors and S1P-induced Ca2+ responses in primary rat cortical 
astrocytes.  
(A) RT-PCR analysis for metabotropic S1P receptors by RT-PCR. Marker (M) shows the 100 bp 
DNA size ladder. (B-E) Ca2+ responses to S1P at the indicated concentrations (0.01–10 µM). (F) 
Intracellular Ca2+ level after treatment with the selective S1P1 agonist SEW2871 (10 µM). (G-J) 
Representative traces and quantitative data of peak Ca2+ amplitude and sustained Ca2+ 
concentration due to S1P (1 µM)-induced Ca2+ mobilization after treatment with selective S1P2 
inhibitor JTE013 (1 µM) (G), selective S1P3 inhibitor CAY10444 (10 µM) (H), PLC inhibitor 
U73122 (1 µM) (I), or Gβγ subunit activity inhibitor gallein (10 µM) (J). *P < 0.05, **P < 0.01 vs. 
S1P alone (n = 6–16). Drugs were applied during the periods indicated by the horizontal lines. 
 
Fig. 2. Involvement of TRPC channels in S1P-induced Ca2+ responses in cultured rat astrocytes.  
(A) S1P-induced Ca2+ responses under extracellular Ca2+-free conditions. (B, C) Representative 
traces and quantitative data of peak Ca2+ amplitude and sustained Ca2+ concentration due to S1P (1 
µM)-induced Ca2+ mobilization after treatment with non-selective TRP inhibitor Gd3+ (10 µM) 
(B) or La3+ (10 µM) (C). (D) RT-PCR analysis of TRPC channels in primary rat cortical 
astrocytes. (E, F) Astrocytes were treated with non-selective TRPC inhibitor Pyr2 (10 µM) (E) or 
selective TRPC3 inhibitor Pyr3 (3 µM) (F). *P < 0.05, **P < 0.01 vs. S1P alone (n = 3–13). 
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Fig. 3. S1P-induced morphological changes in cultured rat astrocytes. Representative 
photographs were obtained from serum-starved rat cortical astrocytes that received control 
treatment (A), S1P at 1 µM (B), S1P and BAPTA-AM at 3 µM (C), S1P and Pyr2 at 10 µM (D), 
or S1P and Pyr3 at 10 µM (E) for 3 h. The actin cytoskeleton was detected by phalloidin staining, 
shown in green fluorescence. Cellular nuclei were stained with Hoechst 33342, as shown in blue 
fluorescence. Scale bar, 50 µm. Note that cultured astrocytes display process-bearing stellate cells 
under serum starvation, and change into polygonal morphology in response to S1P. (F) 
Quantification of the percentage of polygonal cells in the presence or absence of the indicated 
drugs. ***P < 0.001 vs. control (n = 3–5). 
 
Fig. 4. S1P-induced astrocytic migration in cultured rat astrocytes. Astrocytic migration was 
measured by scratch-wound assay. Astrocytes were treated with FBS (0%) (control) or the 
indicated drugs for 72 h following serum starvation. Representative photographs were obtained at 
0 and 72 h. The areas of astrocytic migration were normalized to that of the control cells grown in 
EMEM containing FBS (10%) for 72 h. The depicted area of migration is representative of three 
independent experiments performed in 4–8 wells in one experiment. Scale bar, 100 µm. 
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Fig. 5. Changes in mRNA expression levels and CXCL1 release into astrocyte culture medium 24 
h after S1P treatment. 
(A-H) mRNA levels of BDNF (A), GDNF (B), NGF (C), COX2 (D), ICAM1 (E), IL6 (F), CCL5 
(G), and CXCL1 (H) in rat primary astrocytes that received control treatment or S1P (1 µM) for 
24 h. *P < 0.05 vs. control (n = 4–7). (I) CXCL1 release in the astrocyte culture medium was 
measured by ELISA assay. Astrocytes were treated with control media, S1P (1 µM), S1P and 
S1P1 antagonist VPC44116 (VPC; 1 µM), S1P and S1P2 antagonist JTE013 (JTE; 1 µM), or S1P 
and S1P3 antagonist CAY10444 (CAY; 10 µM). *P < 0.05, ***P < 0.001 vs. control, ###P < 
0.001 vs. S1P alone (n = 4). 
 
Fig. 6 Involvement of TRPC6, Ca2+ signaling, and the MAPK pathways in S1P- induced CXCL1 
release. 
(A) S1P-induced activation of MAPK pathways. Astrocytes were treated with control media or 1 
µM S1P for 10 min (p38) or 30 min (ERK, JNK). Cell lysates were immunoblotted for 
phosphorylated MAPK proteins (p-ERK, p-JNK, p-p38) or total MAPK proteins (t-ERK, t-JNK, 
t-p38). Each value is expressed as the ratio of the phosphorylated MAPK protein level to the 
corresponding total MAPK protein level and the control value was set to 1. *P < 0.05 vs. control 
(n = 3-5). (B-E, J,O) Astrocytes were treated with control media, S1P (1 µM), S1P and MEK 
inhibitor PD98059 (PD; 30 µM), JNK inhibitor SP600125 (SP; 30 µM), or p38 inhibitor 
SB203580 (SB; 30 µM) (B), S1P and Pyr2 (1–10 µM) (C), S1P and Pyr3 (1–10 µM) (D), S1P and 
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PKC inhibitor bisindolylmaleimide I (BIM; 1 µM), endoplasmic reticulum Ca2+-ATPase inhibitor 
CPA (30 µM), or intracellular Ca2+ chelator BAPTA-AM (3 µM) (E), or OAG (1-100 µM) (J). 
CXCL1 release in the astrocyte culture medium was measured by ELISA assay. ***P < 0.001 vs. 
control, #P < 0.05, ###P < 0.001 vs. S1P alone (n = 4-5). (F) TRPC6 mRNA expression in 
astrocytes treated with control siRNA or siRNA for 72 h. ***P < 0.001 vs. control siRNA (n = 8–
9). (G, H) Representative traces of Ca2+ responses to OAG (100 µM) in astrocytes treated with 
control siRNA (G) or TRPC6 siRNA (si-TRPC6) (H) for 72 h. (I) Percentages of astrocytes 
treated with siRNA or si-TRPC6 that respond to OAG (100 µM) treatment for 10 min. *P < 0.05 
vs. control siRNA (n = 6–9). (K-N) Representative traces (K, L) and quantitative data of peak 
Ca2+ amplitude (M) and sustained Ca2+ concentration (N) due to S1P (1 μM) in astrocytes treated 
with control siRNA (K, M, N) or si-TRPC6 (L-N) for 72 h. *P < 0.05 vs. control siRNA (n = 4). 
(O) CXCL1 release from astrocytes treated with siRNA or si-TRPC6 for 72 h after 24 h of control 
treatment or S1P (1 µM). ***P < 0.001 vs. control siRNA-treated control, ###P < 0.001 vs. 
control siRNA-treated S1P (n = 5). 
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